Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes.
Griffith, D.A., Kung, D.W., Esler, W.P., Amor, P.A., Bagley, S.W., Beysen, C., Carvajal-Gonzalez, S., Doran, S.D., Limberakis, C., Mathiowetz, A.M., McPherson, K., Price, D.A., Ravussin, E., Sonnenberg, G.E., Southers, J.A., Sweet, L.J., Turner, S.M., Vajdos, F.F.(2014) J Med Chem 57: 10512-10526
- PubMed: 25423286 
- DOI: 10.1021/jm5016022
- Primary Citation of Related Structures:  
4WYO, 4WZ8 - PubMed Abstract: 
Acetyl-CoA carboxylase (ACC) inhibitors offer significant potential for the treatment of type 2 diabetes mellitus (T2DM), hepatic steatosis, and cancer. However, the identification of tool compounds suitable to test the hypothesis in human trials has been challenging ...